Pharma News

Scientists have identified a protein that could be the key in the development of Alzheimer's disease. The findings were published in Science Translational Medicine. GPR3, the protein is believed to play an important role in reducing the buildup of amyloid plaques in the brain, a hallmark of Alzheimer's disease.

Researchers have now revealed that people with high stress jobs have a 22% higher risk of stroke than those with low stress jobs. The study appeared online in Neurology.

[adsense:336x280:8701650588]

Lithium, a drug used successfully for decades to treat adults with bipolar disorder, can also be safe and effective for children suffering from the chronic brain condition. The study was published in Pediatrics.

The mosquito-borne parasite that causes malaria also produces a protein that could help stop cancer, new research has found.

Nestle India on Friday said all samples of its Maggi noodles have passed the required tests as directed by the Bombay High Court but it would hit the market after some time as the newly-manufactured product has to go through fresh tests.

Nestle India said on Friday that 100 percent of the Maggi instant noodles' samples tested in three laboratories have been cleared and that the noodles are safe for human consumption.

Researchers say that both belief in God and prejudice towards immigrants can be reduced by directing magnetic energy into the brain. People often turn to ideology when they are confronted by problems. The research was published in the journal Social Cognitive and Affective Neuroscience.

Merck, a leading science and technology company relaunch its brand identity. It will introduce  new logo reflect the transformation into a global science and technology company. Outside the United States and Canada, the company will operate uniformly as Merck.

A new study has revealed that increasing insulin dose to manage diabetes was found not to be associated with increased cardiovascular death. The findings were published in Diabetes Care.

Roche Pharma India recently introduce  two innovative medicines for the treatment of HER2-positive metastatic breast cancer, a particularly aggressive form of the disease. The new drugs, Perjeta and Kadcyla, have been shown to both extend survival and improve quality of life in their approved applications for metastatic HER2-positive breast cancer.